Chronic Lymphocytic Leukemia

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its first...

TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo). U2 Combo application seeks approval for chronic...

H.C. Wainwright maintains Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) as it welcomes the company’s amendment of a cancer study called GENUINE. Under GENUINE, TG is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in patients with previously treated high-risk...